{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-001909","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2024-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.178901+00:00","generated_at":"2026-06-06T19:57:13.471846+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Zevra Therapeutics appoints Alvin Shih, M.D. to board of directors","bullets":["Dr. Alvin Shih appointed as Class III director effective January 20, 2024.","Shih has rare disease experience, former COO of Pfizer's Rare Disease Research Unit.","Initial option grant of 58,800 shares vesting over 3 years, annual retainer $40,000.","Shih will receive additional option of 39,200 shares annually while serving on board.","No family relationships or transactions requiring disclosure under Item 404(a)."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-001909","json":"https://secwatch.observer/filing/0001437749-24-001909.json","markdown":"https://secwatch.observer/filing/0001437749-24-001909.md","text":"https://secwatch.observer/filing/0001437749-24-001909.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924001909/0001437749-24-001909-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924001909/zvra20240112_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T19:57:13.471846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e02c887ea6","claim":"Alvin Shih, M.D. was appointed as director at ZEVRA THERAPEUTICS, INC..","evidence_excerpt":"On January 20, 2024, the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) appointed Alvin Shih, M.D. to serve as a director of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924001909/0001437749-24-001909-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}